AMGN News 137.83 08/28/2014 04:31:55 Amgen Inc (AMGN)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 137.83 $AMGN

Final Glance: Biotechnology companies
AP - Wed Aug 27, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Why Amgen (AMGN) Stock Hit a One-Year High Today
at The Street - Wed Aug 27, 9:32AM CDT
Amgen (AMGN) hit a 52-week high of $137.99 on Wednesday after the Food and Drug Administration granted priority review for the company's prospective chronic heart failure treatment drug ivabradine.

Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:

Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.

FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
PR Newswire - Wed Aug 27, 8:15AM CDT
Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 million people in the U.S.2,3

7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 26, 8:56PM CDT
Regeneron Pharmaceuticals held a conference call earlier this month to highlight its second-quarter earnings and give investors some insight into the biotech's prospects for the rest of the year. Here are seven things management wants you to know....

Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:44PM CDT
Kite Pharma, Inc. (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 for aggressive non-Hodgkin's lymphoma.

HCP Boasts Of 29 Years Of Dividend Increases
at Investor's Business Daily - Tue Aug 26, 4:57PM CDT
HCP (HCP) is a real estate investment trust that invests in four health-care sectors: senior housing; post-acute/skilled nursing facilities; life sciences; and medical offices and hospitals. The company manages, acquires, develops and sells...

Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:20PM CDT
Regado Biosciences (RGDO) announced that it is permanently terminating the enrollment process for its phase III study on Revolixys Kit.

VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.

Midday Glance: Biotechnology companies
AP - Tue Aug 26, 12:31PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:

17.2% Return Seen to Date on SmarTrend Amgen Call (AMGN)
Comtex SmarTrend(R) - Tue Aug 26, 11:04AM CDT
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on June 2nd, 2014 at $116.45. In approximately 3 months, Amgen has returned 17.16% as of today's recent price of $136.43.

3 Reasons Amgen Inc.'s Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 8:43AM CDT
Years of patience are finally paying off for Amgen shareholders, whose shares jump by more than 160% over the past three years. AMGN data by YCharts Amgen's shares have rallied on the prospect of delivering late-stage data on 10 new...

3 Reasons Celgene Corporation's Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 7:49AM CDT
If you've been a long-term shareholder in Celgene stock you have very little to complain about. The company's core drug, Revlimid, a treatment for blood-borne cancers, has grown into what's expected to be a $5 billion blockbuster this year, and...

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Cubist Pharmaceuticals' Antibiotic Accepted for EU Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 5:25PM CDT
The EMA accepted Cubist Pharmaceuticals' (CBST) MAA for its investigational antibiotic, ceftolozane/tazobactam.

Amgen Set to Possibly Pullback After Yesterday's Rally of 1.48%
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 1.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 3:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $133.38 to a high of $134.93. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $133.46 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell
PR Newswire - Mon Aug 25, 3:15PM CDT
Western Digital Corp. (NASDAQ: WDC) today announced that chief financial officer Tim Leyden, 62, is retiring after 24 years of distinguished service at the company. He is being succeeded by Olivier Leonetti, 50, who has served as vice president, finance at Amgen Inc. from 2011, after having previously spent 14 years in global finance leadership positions at Dell Inc. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8, 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 115

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 55

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 123

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 77

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 114

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

Anivive's Lab Expansion: Driving Innovation in Veterinary Diagnostics

Updated Category News Views 130

Expanding Horizons in Veterinary Diagnostics Anivive is embarking on an exciting journey as it expands its state-of-the-art laboratory, a move that reflects the soaring demand for its specialized pathology services. This enhancement comes in response to the growing interest in veterinary diagnostics, particularly through its subsidiary, Vidium, known for its leadership in...

Continue Reading
Aurora Chen Joins PBGH as Vice President to Lead Advisory Services

Updated Category News Views 239

Aurora Chen Joins PBGH as Vice President of Advisory Services PBGH, a notable nonprofit coalition, has proudly announced the appointment of Aurora Chen as its Vice President of Advisory Services. Bringing a wealth of experience in the health care and employee benefits sector, Chen is set to lead efforts that expand and enhance the advisory services offered by PBGH. This...

Continue Reading
What Are the Pros and Cons of Using a Financial Planner?

Updated Category Personal Finance Views 654

Are you considering enlisting the help of a financial planner and aren’t sure if it's the right choice for you? Then you need to know about their pros and cons! Financial planners play a vital role in offering you support and guidance with tailor-made plans that help you meet your savings, retirement, or investment goals. We have outlined the pros and cons of a...

Continue Reading
Angel Oak Financial Strategies Trust Announces March 2025 Dividend

Updated Category News Views 113

Introduction to Angel Oak Financial Strategies Income Term Trust Angel Oak Financial Strategies Income Term Trust (FINS) has declared a monthly distribution that investors eagerly anticipate. The closed-end fund listed on the New York Stock Exchange is making headlines as it announces a distribution of $0.109 per share for March. Understanding the mechanics behind such...

Continue Reading
Investors Eye Value Stocks as Federal Reserve Makes Moves

Updated Category News Views 81

Exploring Value Stocks Amid Federal Adjustments Bank of America has underscored three key sectors that stand to gain from the Federal Reserve's unique dual approach of cutting interest rates while profits rise in corporate sectors. This 'rare double whammy of stimulus' could present a significant opportunity for savvy investors keen on value stocks. Key Sector Highlights...

Continue Reading